Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing therapies for neurodegenerative diseases, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025, in New York City. Dr. Will Chou, the company's president and CEO, will deliver a presentation outlining Passage Bio's strategic vision and operational focus during the conference. Additionally, management will engage in one-on-one meetings with investors to discuss their innovative approaches and pipeline developments.

A key highlight of Passage Bio's efforts is the lead product candidate, PBFT02, which aims to address frontotemporal dementia by increasing progranulin levels, thereby restoring lysosomal function and potentially slowing disease progression. This underscores the company's commitment to advancing genetic medicine technologies that target underlying pathologies of neurodegenerative conditions.

For those unable to attend the conference, a video webcast of Dr. Chou's presentation will be available to registered attendees starting September 5, 2025, at 7:00 a.m. ET. Furthermore, the presentation will be accessible for 30 days post-event on the Investors & News section of Passage Bio's website, allowing broader reach among interested stakeholders.

As Passage Bio continues its mission of improving the lives of patients and families affected by neurodegenerative diseases, updates from the conference are anticipated to provide valuable insights into the company's progress and future prospects. For further inquiries regarding the conference or investor relations, interested parties can contact Stuart Henderson at Passage Bio or Mike Beyer from Sam Brown Inc. Healthcare Communications. For more detailed information about their research and development efforts, the public is encouraged to visit the company’s website at passagebio.com.

As Passage Bio, Inc. (NASDAQ: PASG) prepares for participation in the H.C. Wainwright 27th Annual Global Investment Conference, investors should view this as a pivotal opportunity not only to assess the company’s strategic direction but also to understand its market potential in the neurology sector. The focus on neurodegenerative diseases is both timely and crucial, given the growing prevalence of conditions like frontotemporal dementia.

At the conference, CEO Will Chou, M.D., will provide key insights into Passage Bio's lead candidate, PBFT02, aimed at treating underlying pathologies of neurodegenerative diseases by elevating progranulin levels. This innovative approach positions Passage Bio favorably against competitors, as it tackles disorders through a potentially transformative mechanism rather than symptomatic treatment.

Investors should consider the implications of PBFT02’s clinical efficacy and safety data, which will likely be discussed during one-on-one meetings. As with many clinical-stage biotech companies, the performance of this candidate could significantly influence stock valuation. Positive data releases and regulatory advancements could catalyze significant upward momentum in PASG shares. Conversely, delays or adverse results may lead to volatility.

With an increasing focus on personalized and genetic medicine, Passage Bio stands at the intersection of technology and biotechnology – a sector ripe for innovation and investment. The management's prior presentations and the expected replay accessibility demonstrate their commitment to transparency and investor engagement, which is a substantial plus for institutional investors.

Monitoring how the market reacts post-conference will be critical; a surge in interest could suggest growing confidence in Passage Bio’s strategy. Investors who are attuned to the advancements in gene therapies for neurological conditions should closely follow the company’s developments and consider adjusting their positions accordingly.